CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Shock Team Approach in Refractory Cardiogenic Shock Requiring Short-Term Mechanical Circulatory Support: A Proof of Concept Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR) Classification of Deaths in Cardiovascular Outcomes Trials Known Unknowns and Unknown Unknowns

Clinical Trial2020 Nov 7;41(42):4114-4123.

JOURNAL:Eur Heart J. Article Link

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

J Tuñón, PG Steg, ODYSSEY OUTCOMES Investigators et al. Keywords: chronic kidney disease; glomerular filtration rate; Low-density lipoprotein cholesterol; MACE; PCSK9 inhibition

Full Text PDF